Oral cavity cancer after sublingual buprenorphine use.

Saved in:
Bibliographic Details
Title: Oral cavity cancer after sublingual buprenorphine use.
Authors: Abruzzo AR; Harvard Medical School, Boston, MA, USA; Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Boston, MA, USA., Harris MTH; Grayken Center for Addiction, Section of General Internal Medicine, Clinical Addiction Research and Education Unit, Boston Medical Center, Boston University School of Medicine, Boston, MA, USA., Sroussi HY; Division of Oral Medicine and Dentistry, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA; Oral Medicine and Oral Oncology Treatment Center, Dana-Farber Cancer Institute, Boston, MA, USA., Suzuki J; Division of Addiction Psychiatry, Department of Psychiatry, Brigham and Women's Hospital, Boston, MA, USA., Kass JI; Reliant Medical Group, Worcester, MA, USA., Rettig EM; Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA; Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Boston, MA, USA; Head and Neck Oncology Center, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: emrettig@bwh.harvard.edu.
Source: Oral oncology [Oral Oncol] 2025 Sep; Vol. 168, pp. 107573. Date of Electronic Publication: 2025 Aug 05.
Publication Type: Case Reports; Letter
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 9709118 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0593 (Electronic) Linking ISSN: 13688375 NLM ISO Abbreviation: Oral Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1879-0593
DOI:10.1016/j.oraloncology.2025.107573